Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies

Medicine and Dentistry

• Osimertinib 100%
• Patient 100%
• Non Small Cell Lung Cancer 66%
• Epidermal Growth Factor Receptor 50%
• Disease Exacerbation 33%
• Epidermal Growth Factor Receptor Kinase Inhibitor 33%
• Subgroup Analysis 33%
• Central Nervous System Metastasis 33%
• Therapeutic Procedure 33%
• Combination Therapy 16%
• Adverse Event 16%
• Diarrhea 16%
• Overall Survival 16%
• Cancer Growth 16%
• Silo-Filler's Disease 16%
• Exanthem 16%
• Progression Free Survival 16%
• Coughing 16%
• Treatment Duration 16%
• Decreased Appetite 16%
• Paronychia 16%
• Central Nervous System 16%
• Analysis 16%
• Inpatient 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Osimertinib 100%
• Non Small Cell Lung Cancer 66%
• Epidermal Growth Factor Receptor 50%
• Disease Exacerbation 33%
• Epidermal Growth Factor Receptor Kinase Inhibitor 33%
• Central Nervous System Metastasis 33%
• Phase II Trials 33%
• Adverse Event 16%
• Cancer Growth 16%
• Diarrhea 16%
• Overall Survival 16%
• Coughing 16%
• Progression Free Survival 16%
• Decreased Appetite 16%
• Paronychia 16%
• Lung Disease 16%
• Rash 16%